{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:40Z","timestamp":1791181240307,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10787-015-0229-0","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T11:09:20Z","timestamp":1424171360000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs"],"prefix":"10.1007","volume":"23","author":[{"given":"Sandhya","family":"Jinesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"issue":"1","key":"229_CR1","doi-asserted-by":"crossref","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen KJ, Virkki LM, Malmivaara A et al (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7(1):e30275 pub 2012 Jan 17","journal-title":"PLoS ONE"},{"key":"229_CR001","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780330302","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.\u00a0Arthritis Rheum 33:305\u2013315","journal-title":"Arthritis Rheum"},{"key":"229_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/03009748709102517","volume":"66","author":"F Arenzana-Seisdedos","year":"1987","unstructured":"Arenzana-Seisdedos F, Teyton L, Virelizier JL (1987) Immunoregulatory mediators in the pathogenesis of rheumatoid arthritis. Scand J Rheumatol Suppl 66:13\u201317","journal-title":"Scand J Rheumatol Suppl"},{"issue":"1 Suppl","key":"229_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/03946320140270S102","volume":"27","author":"A Armuzzi","year":"2014","unstructured":"Armuzzi A, Lionetti P, Blandizzi C et al (2014) Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 27(1 Suppl):11\u201332","journal-title":"Int J Immunopathol Pharmacol"},{"key":"229_CR4","doi-asserted-by":"crossref","unstructured":"Behrens F, Ca\u00f1ete JD, Olivieri I et al (2014) Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford). pii: keu415. [Epub ahead of print]","DOI":"10.1093\/rheumatology\/keu415"},{"key":"229_CR5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.clinthera.2010.09.003","volume":"32","author":"EG Boyce","year":"2010","unstructured":"Boyce EG, Halilovic J, Stan-Ugbene O (2010) Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-\u03b1 inhibitor. Clin Ther 32:1681\u20131703","journal-title":"Clin Ther"},{"key":"229_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14712598.3.1.141","volume":"3","author":"J Braun","year":"2003","unstructured":"Braun J, Sieper J (2003) Overview of the use of the anti-TNF\u00a0agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 3:141\u2013168","journal-title":"Expert Opin Biol Ther"},{"key":"229_CR002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"29","author":"FM Brennan","year":"1989","unstructured":"Brennan FM et al (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.\u00a0Lancet 29:244\u2013247","journal-title":"Lancet"},{"key":"229_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","volume":"2","author":"FR Brennan","year":"2010","unstructured":"Brennan FR, Morton LD, Sebastian Spindeldreher S et al (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2:233\u2013255","journal-title":"MAbs"},{"key":"229_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hyb.1987.6.489","volume":"6","author":"TS Bringman","year":"1987","unstructured":"Bringman TS, Aggarwal BB (1987) Monoclonal antibodies\u00a0to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma 6:489\u2013507","journal-title":"Hybridoma"},{"key":"229_CR9","first-page":"209","volume":"2","author":"A Cassinotti","year":"2007","unstructured":"Cassinotti A, Ardizzone S, Porro BG (2007) Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn\u2019s disease. Core Evid 2:209\u2013229","journal-title":"Core Evid"},{"key":"229_CR10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3346\/jkms.2008.23.5.852","volume":"23","author":"C Choi","year":"2008","unstructured":"Choi C, Kim T, Park H et al (2008) Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci 23:852\u2013856","journal-title":"J Korean Med Sci"},{"key":"229_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/mabs.1.2.7909","volume":"1","author":"J Descotes","year":"2009","unstructured":"Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104\u2013111","journal-title":"MAbs"},{"key":"229_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","volume":"52","author":"M Dostalek","year":"2013","unstructured":"Dostalek M, Gardner I, Gurbaxani BM et al (2013) Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52:83\u2013124","journal-title":"Clin Pharmacokinet"},{"key":"229_CR13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M et al (1993) Treatment of rheumatoid\u00a0arthritis\u00a0with chimeric\u00a0monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:681\u2013690","journal-title":"Arthritis Rheum"},{"key":"229_CR14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105\u20131110","journal-title":"Lancet"},{"key":"229_CR15","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4049\/jimmunol.1103298","volume":"188","author":"M Fallahi-Sichani","year":"2012","unstructured":"Fallahi-Sichani M, Flynn JL, Linderman JJ et al (2012) Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 188:3169\u20133178","journal-title":"J Immunol"},{"key":"229_CR16","unstructured":"FDA (2009) Cancer warnings required for TNF blockers. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm175803.htm . Accessed on 19 Jan 2015"},{"key":"229_CR17","unstructured":"FDA Drug Safety Communication (2011) Drug labels for the tumor necrosis factor-alpha (TNF\u03b1) blockers now include warnings about infection with Legionella and Listeria bacteria. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm270849.htm . Accessed on 19 Jan 2015"},{"key":"229_CR18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/stem.5530110206","volume":"11","author":"A Ferrajoli","year":"1993","unstructured":"Ferrajoli A, Talpaz M, Kurzrock R et al (1993) Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells 11:112\u2013119","journal-title":"Stem Cells"},{"key":"229_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.jidsymp.5650029","volume":"12","author":"AB Gottlieb","year":"2007","unstructured":"Gottlieb AB (2007) Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc 12:1\u20134","journal-title":"J Investig Dermatol Symp Proc"},{"key":"229_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-1759(87)90367-X","volume":"96","author":"M Hirai","year":"1987","unstructured":"Hirai M, Okamura N, Terano Y et al (1987) Production and characterization of\u00a0monoclonal antibodies\u00a0to human tumor necrosis factor. J Immunol Methods 96:57\u201362","journal-title":"J Immunol Methods"},{"key":"229_CR21","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"12","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ et al (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 12:1558\u20131565","journal-title":"Rheumatology (Oxford)"},{"key":"229_CR22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2007.00138.x","volume":"20","author":"JM Jackson","year":"2007","unstructured":"Jackson JM (2007) TNF- alpha\u00a0inhibitors. Dermatol Ther 20:251\u2013264","journal-title":"Dermatol Ther"},{"key":"229_CR003","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","volume":"10","author":"J Keffer","year":"1991","unstructured":"Keffer J et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025\u20134031","journal-title":"EMBO J"},{"key":"229_CR23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/ard.2007.072447","volume":"66","author":"W Kievit","year":"2007","unstructured":"Kievit W, Fransen J, Oerlemans AJ et al (2007) The efficacy of anti-TNF in rheumatoid arthritis, a\u00a0comparison\u00a0between randomised controlled trials and clinical practice. Ann Rheum Dis 66:1473\u20131478","journal-title":"Ann Rheum Dis"},{"key":"229_CR24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/01.meg.0000108345.41221.c2","volume":"16","author":"I Kirman","year":"2004","unstructured":"Kirman I, Whelan RL, Nielsen OH (2004) Infliximab: mechanism of action beyond\u00a0TNF-alpha\u00a0neutralization\u00a0in inflammatory bowel disease. Eur J Gastroenterol Hepatol 16:639\u2013641","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"229_CR004","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"DM Knight","year":"1993","unstructured":"Knight DM et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.\u00a0Mol Immunol 30:1443\u20131453","journal-title":"Mol Immunol"},{"key":"229_CR25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"229_CR26","unstructured":"Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online, Hudson, Ohio: Lexi-Comp, Inc. (2014)"},{"key":"229_CR27","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","volume":"33","author":"MA Machado","year":"2013","unstructured":"Machado MA, Barbosa MM, Almeida AM et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33:2199\u20132213","journal-title":"Rheumatol Int"},{"key":"229_CR28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2165\/00003495-200059060-00010","volume":"59","author":"A Markham","year":"2000","unstructured":"Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341\u20131359","journal-title":"Drugs"},{"key":"229_CR29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/hyb.1987.6.305","volume":"6","author":"A Meager","year":"1987","unstructured":"Meager A, Parti S, Leung H et al (1987) Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma 6:305\u2013311","journal-title":"Hybridoma"},{"key":"229_CR30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1476-5381.2010.01099.x","volume":"162","author":"D Mewar","year":"2011","unstructured":"Mewar D, Wilson AG (2011) Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 162:785\u2013791","journal-title":"Br J Pharmacol"},{"key":"229_CR31","author":"TL Michaud","year":"2014","unstructured":"Michaud TL, Rho YH, Shamliyan T et al (2014) The comparative safety of TNF Inhibitors in rheumatoid arthritis\u2014a meta-analysis update of 44 randomized controlled trials. Am J Med. doi: 10.1016\/j.amjmed.2014.06.012 [Epub ahead of print]","journal-title":"Am J Med"},{"key":"229_CR32","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","volume":"151","author":"KM Mohler","year":"1993","unstructured":"Mohler KM, Torrance DS, Smith CA et al (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548\u20131561","journal-title":"J Immunol"},{"key":"229_CR33","first-page":"97","volume":"46","author":"HZ Movat","year":"1987","unstructured":"Movat HZ, Cybulsky MI, Colditz IG et al (1987) Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc 46:97\u2013104","journal-title":"Fed Proc"},{"key":"229_CR34","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","volume":"69","author":"JL Nam","year":"2010","unstructured":"Nam JL, Winthrop KL, van Vollenhoven RF et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976\u2013986","journal-title":"Ann Rheum Dis"},{"key":"229_CR35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74:354\u2013360","journal-title":"Ann Rheum Dis"},{"issue":"(5 Suppl1)","key":"229_CR36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","volume":"34","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34((5 Suppl1)):12\u201318","journal-title":"Semin Arthritis Rheum"},{"key":"229_CR37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","volume":"10","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Feagan BG, Sandborn WJ (2012) Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10:1079\u20131087","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"229_CR38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.1.2.6","volume":"2012","author":"H Raja","year":"2012","unstructured":"Raja H, Matteson EL, Michet CJ et al (2012) Safety of tumor necrosis factor inhibitors during pregnancy and breastfeeding. Transl Vis Sci Technol 2012(1):6","journal-title":"Transl Vis Sci Technol"},{"key":"229_CR39","first-page":"S58","volume":"28","author":"R Rau","year":"2010","unstructured":"Rau R (2010) Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol 28:S58\u2013S64","journal-title":"Clin Exp Rheumatol"},{"key":"229_CR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H","volume":"50","author":"A Raza","year":"2000","unstructured":"Raza A (2000) Anti-TNF therapies in rheumatoid arthritis, Crohn\u2019s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 50:229\u2013235","journal-title":"Microsc Res Tech"},{"key":"229_CR41","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762\u2013784","journal-title":"Arthritis Rheum"},{"key":"229_CR42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","volume":"322","author":"J Saklatvala","year":"1986","unstructured":"Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547\u2013549","journal-title":"Nature"},{"key":"229_CR005","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780310816","volume":"31","author":"T Saxne","year":"1988","unstructured":"Saxne T et al (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041\u20131045","journal-title":"Arthritis Rheum"},{"key":"229_CR43","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.167.4.1511","volume":"167","author":"P Seckinger","year":"1988","unstructured":"Seckinger P, Isaaz S, Dayer JM (1988) A human inhibitor of tumor necrosis factor alpha. J Exp Med 167:1511\u20131516","journal-title":"J Exp Med"},{"key":"229_CR44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tibtech.2013.10.002","volume":"32","author":"O Spadiut","year":"2013","unstructured":"Spadiut O, Capone S, Krainer F et al (2013) Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 32:54\u201360","journal-title":"Trends Biotechnol"},{"key":"229_CR006","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","volume":"89","author":"GJ Thorbecke","year":"1992","unstructured":"Thorbecke GJ et al (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci 89:7375\u20137379","journal-title":"Proc Natl Acad Sci"},{"key":"229_CR45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Eric H et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"229_CR46","first-page":"1341","volume":"2","author":"EG Trehu","year":"1996","unstructured":"Trehu EG, Mier JW, Dubois JS et al (1996) Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 2:1341\u20131351","journal-title":"Clin Cancer Res"},{"key":"229_CR47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.jidsymp.5650031","volume":"12","author":"RS Wallis","year":"2007","unstructured":"Wallis RS (2007) Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 12:16\u201321","journal-title":"J Investig Dermatol Symp Proc"},{"key":"229_CR007","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","volume":"89","author":"RO Williams","year":"1992","unstructured":"Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.\u00a0Proc Natl Acad Sci 89:9784\u20139788","journal-title":"Proc Natl Acad Sci"},{"key":"229_CR48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","volume":"126","author":"M Wong","year":"2009","unstructured":"Wong M, Ziring D, Korin Y, Desai S et al (2009) TNF\u03b1 blockade in human diseases: mechanisms and future directions. Clin Immunol 126:121\u2013136","journal-title":"Clin Immunol"},{"key":"229_CR49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"MA Xixi","year":"2013","unstructured":"Xixi MA, Shengqian XU (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1:177\u2013184","journal-title":"Biomed Rep"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-015-0229-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-015-0229-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-015-0229-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T02:15:01Z","timestamp":1691288101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-015-0229-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,17]]},"references-count":56,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s10787-015-0229-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,17]]}}}